{"task_id": "033472e1313a64f8", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 178/464)", "text": "e aggressive course\n166\nAcute Myelogenous Leukemia\n\n--- Page 188 ---\nHEMATOLOGIC MALIGNANCIES OVERVIEW (CONT\u2019D)\n\u0002\nCHRONIC\nLEUKEMIA\ninvolves mature differen\ntiated cells. More indolent course\nLYMPHOMA\nmalignancy of lymphoid origin and\npresents more in lymphoid organs\n\u0002 HODGKIN\u2019S LYMPHOMA\nB cell (Reed Sternberg cell)\n\u0002\nNON-HODGKIN\u2019S LYMPHOMA\nB, T, or NK cells\n*lymphoblastic lymphoma (LL) = acute lympho\nblastic leukemia (ALL). Small lymphocytic lym\nphoma (SLL) = chronic lymphocytic leukemia (CLL)\nPATHOPHYSIOLOGY\nEPIDEMIOLOGY\n\u0002\nINCIDENCE\n1 2% of all cancers, 90% of all acute\nleukemias in adulthood, mean age 65\n\u0002\nMORTALITY\n1.5% of all cancers\nRISK FACTORS FOR AML\n\u0002\nFAMILY HISTORY\nfamily history (3\u0003), Down\u2019s, Kli\nnefelter, Fanconi syndrome, Bloom\u2019s, ataxia telan\ngiectasia, neurofibromatosis\n\u0002\nENVIRONMENTAL\nprevious chemotherapy (alkylat\ning agents [melphalan, cyclophosphamide, chlor\nambucil, temozolomide], topoisomerase II inhibitors\n[anthracyclines, etoposide]), radiation, benzene\n\u0002\nDISEASES\nMDS, MPS (PRV, CML, ET, MF), PNH,\naplastic anemia\nDISTINGUISHING FEATURES BETWEEN TREAT\nMENT INDUCED AMLs\nAlkylating\nagents\nTopoisomerase II\ninhibitors\nLatency\n5 7 years\n2 3 years\nMDS pre AML\nYes\nNo\nAML types\nAll, M1 2\nM4 5\nKaryotype\n5, 7\n11q23, 21q22, inv16\nPrognosis\nWorse\nPoor except for\nInv16 karyotype\nCLINICAL FEATURES\nPANCYTOPENIA\nweakness,\nfatigue,\ninfections,\ngingival bleed, ecchymosis, epistaxis, menorrhagia\nBONE PAIN\nribs, sternum, long bones\nCUTANEOUS LESIONS\nleukemic cutis (especially M4,\nM5), chloromas (skin local collection of blasts, granulo\ncytic sarcoma especially M2), gum hypertrophy (M5)\nCNS LEUKEMIA (especially M4, M4EO, and M5)\nDIC\nassociated with M3 subtype\nNOTE: lymphadenopathy, hepatosplenomegaly not\ncommon\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, smear (Auer rods), lytes, urea, Cr,\nCa, PO4, Mg, uric acid, albumin, urinalysis, LDH,\nINR, PTT, fibrinogen\nINVESTIGATIONS (CONT\u2019D)\n\u0002\nBONE MARROW BIOPSY (>20% BLASTS) WITH CYTO-\nGENETIC ANALYSIS\nSPECIAL\n\u0002\nIMAGING\nMUGA scan\n\u0002\nLUMBAR PUNCTURE\nCSF for cytology (risk of CNS\ninvolvement greatest with high circulating blasts,\nelevated LDH, and monocytic variants of AML)\n\u0002 HLA TESTING\nto assist in obtaining HLA matched\nplatelets if needed during treatment and to find\nHLA matched allogeneic bone marrow\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nDIAGNOSTIC\nCRITERIA\n>20%\nblasts in bone\nmarrow\nHISTOLOGIC TYPE\n\u0002 FAB M0\nAML, minimally differentiated\n\u0002 FAB M1\nAML, without maturation (19%)\n\u0002 FAB M2\nAML, with maturation (32%)\n\u0002 FAB M3\nacute promyelocytic leukemia (PML),\nwith both hypergranular and variant microgranu\nlar subtypes (M3v)\n\u0002 FAB\nM4\nacute\nmyelomonocytic\nleukemia\n(AMML), including the variant AMML with abnor\nmal eosinophils (M4EO) (17%)\n\u0002 FAB M5\nacute monoblastic leukemia, including\npoorly differentiated (M5a) and differentiated (M5b)\n\u0002 FAB M6\nacute erythroleukemia\n\u0002 FAB M7\nacute megakaryoblastic leukemia\nPROGNOSTIC FACTORS\n\u0002\nGOOD RISK (70% 5 year survival, 33% relapse)\nfavorable karyotypes t(8;21), t(15;17), inv(16)/\nt(16;16)/del(16q), FAB M3\n\u0002\nINTERMEDIATE\nRISK (48% 5 year survival, 50%\nrelapse)\nneither good nor bad; normal cytoge\nnetics or trisomy 8\n\u0002\nPOOR RISK (15% 5 year survival, 78% relapse)\nadverse karyotypes include monosomy chromo\nsome 5 or chromosome 7, del(5q), abn(3q26),\nt(6;9), 11q23 aberrations except for t(9;11), or mul\ntiple chromosomal changes, resistant disease after\nfirst course of chemotherapy (>15% blasts)\n\u0002\nADDITIONAL POOR PROGNOSTIC FACTORS\nage >60,\nKarnofsky score <60%, CD34+, MDR1+, FLT3\nmutation, prior MDS, MPS, chemotherapy, radia\ntion, trisomy 8, t(6;9), LDH >2.9\u0003 UNL\nMANAGEMENT\nAGE <60\n\u0002\nINDUCTION CHEMOTHERAPY\nIDAC (also known as\nthe 7+3 regimen, cytarabine \u00037 days + one of\ndaunorubicin/idarubicin/mitoxantrone \u00033 days),\nHDAC (same except higher dose of cytarabine\nq12h \u000312 doses leads to longer disease free survi\nval) or NOVE (mitoxantrone plus etoposide)\nAcute Myelogenous Leukemia\n167", "text_length": 3910, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 178/464)", "type": "chunk", "chunk_index": 177, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.490434", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.491334", "status": "complete", "chunks_added": 3}